INTRODUCTION
============

Undifferentiated pleomorphic sarcomas (UPS), one of the entities previously included in the effete diagnosis of malignant fibrous histiocytoma (MFH), most commonly occurs in deep soft tissue of extremities (thigh) of elderly patients (average 50-70 years). So-called MFH was in the past thought to be of fibrohistiocytic origin; however, further studies (electron microscopy, immunohistochemical techniques, or molecular studies) failed to demonstrate evidence of "fibrohistiocytic" differentiation. Additionally, other unrelated poorly differentiated sarcoma was included in this entity, compounding the non-specific and confusing nature of this diagnostic term. MFH was declassified by World Health Organization (WHO) in 2012, and is no longer listed as a diagnostic entity. Many tumors previously included as MFH have been reclassified as "undifferentiated pleomorphic sarcoma". [@B001]

Primary sarcomas in lung are rare (less than 0.5% of all lung cancers)[@B002], and primary pulmonary undifferentiated pleomorphic sarcomas (PPUPS) are one of the least common primary lung sarcomas, with 84 reported cases in the English literature ([Table 1](#t01){ref-type="table"}). Weiss SW and Enzinger FM first described soft tissue MFH of 200 cases in 1978.[@B003] A year later, Bedrossian et al.[@B004] reported the first case of primary pulmonary MFH (PPMFH) in a 51-year-old man.

###### Helpful ancillary tests to differentiate tumors with sarcomatoid features

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tumor                                              Immunohistochemistry                                                                              Molecular
  -------------------------------------------------- ------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------
  Sarcomatoid Carcinoma (SC)                         P63+, P40+, PanKeratin+, TTF1+, epithelial markers (MOC31, BerEP4, BG8, B72.3, monoclonal CEA)+   Gains at chromosomes 8q, 7, 1q, 3q, and 19.\
                                                                                                                                                       KRAS mutation, EGFR mutation

  Sarcomatoid Mesothelioma                           WT1+, CK5/6+, D2-40+, calretinin+                                                                 Inactivation of CDKN2A at 9p21 on PCR

  Angiomatoid fibrous histiocytoma (AFH)             Desmin+/-, CD68+/-, EMA+/-                                                                        EWSR1-CREB1, EWSR1-ATF1, or FUS-ATF1 fusion

  Synovial sarcoma (SS)                              TLE1+, Keratin+, EMA+, S100+/-, CD56+, CD99+, Calretinin+/-                                       t(X;18) involving SS18 (SYT) gene

  Epithelioid Sarcoma (ES)                           Loss INI, EMA+, Keratin+/-, CD34+/-                                                               SMARCB1 (INI1) gene alterations on (22q11)

  Dedifferentiated liposarcoma (DDLPS)               MDM2+, CDK4+, SMA+/-, Desmin+/-                                                                   Ring and giant marker chromosomes derived from amplification of 12q13--15 (variable amplification of MDM2, SAS, CDK4, HMGA2)

  Anaplastic large-cell lymphoma (ALCL)              CD45+, CD30+, ALK+/-                                                                              TCR gene rearrangement, Rearrangement of 2p23 (ALK)

  Inflammatory myofibroblastic tumor (IMT)           ALK+/-, SMA+/-, Desmin+/-                                                                         Rearrangement of 2p23 (ALK)

  Ewing Sarcoma                                      FLI1+, CD99+                                                                                      t(11;22) and other translocations involving EWSR1 gene

  Melanoma                                           S100+, SOX10+, MelanA/MART1+, MITF+, Tyrosinase+                                                  BRAF, ARID2, BAP1, GNAQ, HRAS, KIT, NF1, NRAS, and PTEN mutations

  Malignant peripheral nerve sheath tumors (MPNST)   S100+/-, GFAP+/-. CD34+/-                                                                         Complex

  Solitary fibrous tumor (SFT)                       STAT6+, CD34+, BCL2+                                                                              NAB2-STAT6 fusion

  Leiomyosarcoma (LMS)                               SMA+, Desmin+, Caldesmon+                                                                         Complex

  Rhabdomyosarcoma (RMS)                             Desmin+, Myogenin+, MyoD1+                                                                        Complex

  Angiosarcoma                                       Vascular markers (CD31, CD34, FLI1, ERG)+, Keratin +/- in epithelioid angiosarcoma                MYC (8q24) or FLT4 (VEGFR3) (5q35) amplification, Upregulation of vascular-specific receptor tyrosine kinases (TIE1, KDR, TEK, FLT1)

  Kaposi Sarcoma                                     HHV8 (LANA)+, vascular markers+, Lymphatic markers (D2-40, LYVE1, Prox1)+                         KSHV/HHV8 with PCR

  Epithelioid hemangioendothelioma (EHE)             Vascular markers+, TFE3+/-, Keratin +/-                                                           WWTr1-CAMTA1 fusion, YAP1-TFE1 fusion

  Alveolar soft part sarcoma (ASPS)                  TFE3+, Desmin+/-                                                                                  der(17)t(X;17)(p11.2;q25) translocation (ASPSCR1-TFE3 fusion)

  Perivascular epithelioid cell tumor (PEComa)       SMA+, Desmin+, HMB45+, MITF+, MART1+                                                              TSC2 mutations, TFE3 gene fusions
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Yousem and Hochholzer[@B005] reported the most extensive series of primary malignant fibrous histiocytomas in the lung in 1987 with 22 cases (patient age range of 18 to 80 years). Previous irradiation is a known pathogenic risk factor for soft tissue UPS. Similarly, few reports are available in the literature regarding patients who develop PPUPS years after radiation therapy for another tumor.[@B006]^,^[@B007] It is unclear whether de-novo PPUPS and radiation associated undifferentiated pleomorphic sarcomas represent the same entity.

Clinical presentations in pulmonary tumors, as with other types of lung cancers, depends more on the tumor location rather than the histological type. Primary pulmonary sarcomas often present as a large peripheral or hilar well-circumscribed mass, and may present as an endobronchial tumor in 10% of cases.[@B008] The majority of patients present with symptoms of cough, chest pain, hemoptysis, or dyspnea. Radiologic findings can show a solitary mass with or without post-obstructive effects (recurrent pneumonia, bronchiectasis, lobar or segmental atelectasis), and in some cases with extraluminal growth and/or local invasion into adjacent structures.[@B001]

Since clinical and radiographic features of these tumors are nonspecific, pathological tissue examination is required to differentiate them from the much more common epithelial tumors of the lung. The clinical course of these tumors is generally rapidly progressive and metastasis is common.[@B004] The majority of patients die within a period of 1 to 72 months. Endobronchial masses showed more favorable prognosis compare to other origins.[@B008]

Here we report the only case of PPUPS that was diagnosed at UCLA from 2002 to 2019.

CASE REPORT
===========

A 66-year-old man who presented with right sided chest wall pain, weight loss (7 kg), fatigue, and night sweats, without any significant past medical history, was found to have normocytic anemia and a large right inferior hemithorax mass on chest X-ray, which was inseparable from the right hemidiaphragm ([Figure 1](#g01){ref-type="fig"}).

![Chest X-Ray (A) anteroposterior view; (B) lateral view showing a large right lower lung mass.](autopsy-09-03e2019110-g01){#g01}

Computed tomography (CT) scan showed a large (15 × 13.6 × 6.2 cm), poorly circumscribed, heterogeneous mass within the right base of the lung involving the pleural surface and mildly protruding into the 8^th^ and 9^th^ intercostal spaces, without eroding of the adjacent bones ([Figure 2](#g02){ref-type="fig"}). Positron emission tomography--computed tomography (PET-CT) scan revealed a large right inferior hemithorax mass with intense fluorodeoxyglucose (FDG) uptake (standardized uptake values (SUVs) of 22.3). The mass abutted the right hemidiaphragm and the chest wall with suggestion of extension into the rib interspaces, most prominent at the right 8^th^ rib interspace. A 6.1 cm right superior paramediastinal mass with intense FDG uptake (SUVMax 16.3) was also seen, suspicious for pleural deposit/metastatic disease ([Figure 2](#g02){ref-type="fig"}).

![Imaging study of the thorax. CT scan (A - axial plane, C - coronal plane) shows a 15 × 6 cm poorly circumscribed right lower lung mass protruding into the 8^th^ and 9^th^ intercostal spaces. (B - axial plane and D - coronal plane) PET scan shows a 15 cm right inferior lung mass and a 6 cm right superior paramediastinal mass with high FDG uptake.](autopsy-09-03e2019110-g02){#g02}

A CT guided core biopsy was subsequently performed. Histological examination revealed a poorly differentiated malignant neoplasm with epithelioid morphology ([Figure 3](#g03){ref-type="fig"}). Microscopic examination did not reveal any line of differentiation by morphology or upon application of immunohistochemistry; tumoral cells were negative for TTF-1, epithelial (pankeratin, EMA, CAM5.2), mesothelial (calretinin), melanocytic (S100 protein, SOX10, MART1), vascular (CD34), and myogenic (desmin, caldesmon) markers. Therefore, the favored diagnosis was poorly differentiated malignant epithelioid neoplasm.

![Photomicrograph of the CT-Guided biopsy showed a poorly differentiated malignant epithelioid neoplasm (H&E, 10X).](autopsy-09-03e2019110-g03){#g03}

Subsequently, the patient underwent surgical wedge resection of right lower and middle lobes, along with the adjacent right chest wall. Gross examination showed a well-circumscribed light tan and firm mass with areas of necrosis and hemorrhage, which abutted the bone without any gross or microscopic evidence of invasion. The mass measured 17.5 cm × 6.5 cm × 1.5 cm ([Figure 4](#g04){ref-type="fig"}).

![Gross examination of the lung mass resection.](autopsy-09-03e2019110-g04){#g04}

Representative sections showed a vaguely nodular mass consists of spindle to epithelioid neoplastic cells arranged in sheets and fascicles some in a storiform pattern. Large, bizarre pleomorphic cells with round to oval nuclei, prominent nucleoli, and moderate amounts of cytoplasm were observed ([Figure 5A](#g05){ref-type="fig"} and [5B](#g05){ref-type="fig"}). Areas of necrosis ([Figure 5C](#g05){ref-type="fig"}) and high mitotic activity, including atypical mitosis ([Figure 5D](#g05){ref-type="fig"}), were identified.

![Photomicrographs of the tumor showing in **A --** Vaguely nodular high-grade spindle to epithelioid neoplasm with adjacent rib bone (H&E, 3X); **B --** Neoplastic cells with adjacent normal lung parenchyma (H&E, 14X); **C --** Undifferentiated pleomorphic sarcoma with areas of necrosis (H&E, 10X); **D --** Pleomorphic cells with high mitotic activity, atypical mitoses, chronic inflammatory cell infiltrate and focal necrosis (H&E, 12.5X).](autopsy-09-03e2019110-g05){#g05}

All surgical margins were free of malignancy and no lymph node metastasis was identified. As with the biopsy, the neoplastic cells did not show any immunoreactivity to epithelial, mesothelial, or glandular markers; negative staining for pankeratin, CAM5.2, Keratin 5/6, p63, calretinin, WT1, D2-40, TTF1, S100, SOX10, MART1, HMB45, desmin, caldesmon, EMA, CD34, STAT6, C-Kit, DOG1, myogenin, MyoD1, CD21, CD23, CD35, chromogranin, TLE1, BCL2, and CD99 ([Figure 6](#g06){ref-type="fig"}). Since no evidence of extrapulmonary origin was identified and the tumor did not demonstrate any line of differentiation in our extensive work up, the diagnosis of primary pulmonary undifferentiated pleomorphic sarcoma (PPUPS) was rendered.

![Photomicrographs of the tumor. Immunohistochemistry studies shows no line of differentiation (Magnification x10).](autopsy-09-03e2019110-g06){#g06}

Final Pathologic Diagnosis: (i) Undifferentiated pleomorphic sarcoma, high grade, 17.5 cm; (ii) Surgical margins are uninvolved.

The patient was further treated with radiotherapy and multiple cycles of adjuvant chemotherapy (7 days cycle per month with Ifosfamide 1500mg/m2 CIV on days 1-7). Patient tolerated the treatment without any evidence of local recurrence or metastasis up to this date (4 months follow up).

DISCUSSION
==========

Primary lung sarcomas are rare, and represents less than 0.5% of lung malignancies. Cameron[@B009] and Miller and Allen[@B010] reported primary lung sarcomas in 0.15% and 0.3% of lung neoplasms in studies of 6000 and 10134 patients with primary lung malignancies respectively. Among the primary pulmonary sarcomas, undifferentiated pleomorphic sarcoma (UPS) is one of the rarest one with less than 84 reported cases. UPS is defined as a high-grade pleomorphic neoplasm that shows no discernible microscopic evidence of any specific form of differentiation (e.g., lipoblasts, bone formation, epithelial structures) using currently available diagnostic techniques. Fletcher CD in a retrospective study on re-analysis of 159 tumors showed that just 26% of previously diagnosed MFH cases were "true" UPSs, and more than half of cases showed an identifiable line of differentiation.[@B011] The main core of diagnosis of UPS is to exclude other malignant tumors that display similar morphological findings such as malignant melanomas, sarcomatoid carcinomas, anaplastic lymphomas, sarcomatoid mesotheliomas, or other sarcomas (e.g., dedifferentiated liposarcoma and pleomorphic rhabdomyosarcoma, etc.). Therefore, it is a diagnosis of exclusion, which requires careful examination of tissue and generous sampling of the specimen to stablish a correct diagnosis.[@B012] This diagnosis should not be made definitively on a biopsy specimen, because the entire mass is not present in the biopsy materials. Some authors believe that the category of UPS serves primarily as a "wastebasket" for a heterogeneous group of unclassifiable neoplasms with pleomorphic morphology.[@B013]

UPS characteristically shows positive staining for histiocytic markers (CD68, α1-antichymotrypsin, vimentin), a reason why such tumors were identified as "malignant fibrous histiocytoma" (MFH) in the past. Staining for TTF-1, S-100 protein, desmin, actin, myoglobin, caldesmon, D2-40, and calretinin is negative. In some cases, keratin staining may be positive, which makes it difficult to differentiate sarcomatoid carcinomas (SCs) from UPS. Stronger cytokeratin immunoreactivity along with more differentiated carcinomatous elements, as well as immunoreactivity to other epithelial markers (such as P63) can be helpful in the diagnosis of SCs. A wider than usual panel of immunohistochemical studies is necessary to rule out other neoplasms that can resemble UPS including other types of sarcomas, sarcomatoid carcinoma, melanoma, or mesothelioma. ([Table 1](#t01){ref-type="table"}). Special staining, electron microscopy, or microscopy with ultraviolet surface excitations have not shown strong utility in the diagnosis of UPSs.[@B014]^,^[@B015].

Non-specific small droplets of neutral fat and PAS-positive, diastase-resistant droplets may be seen especially in the giant cells in this tumor, which probably reflect a degenerative change.[@B014] Electron microscopic features are helpful for evaluation of better-differentiated tumors; for example, high aspect ratio surface microvilli, perinuclear tonofilaments, and hyaluronic acid crystals are seen in more differentiated mesotheliomas. However, when the tumor is poorly differentiated, the ultrastructural findings are rarely helpful.[@B016] The genetic profile of primary pulmonary mesenchymal tumors shows complex and nonspecific cytogenetic aberrations, similar to their soft tissue counterparts. Molecular studies can be helpful to rule out other tumors with similar histological findings ([Table1](#t01){ref-type="table"}). Molecular mechanisms responsible for primary pulmonary UPS formation and progression are unknown.[@B014]

It is also important to know that UPS is a relatively common soft tissue tumor and most cases of UPS found in the lung represent metastasis from an extra-pulmonary origin.[@B006] Therefore, a careful clinical evaluation to exclude a possible extrapulmonary site of origin is necessary before diagnosing primary pulmonary UPS (PPUPS).

We provide a brief review of literature on PPUPS (previously described as PPMFH) in [Table 2](#t02){ref-type="table"}. 85 cases have been reported in the English literature since 1979, including our case. 51 out of 85 case were male and 35 were female (M:F ratio of 1.45). The patient age ranged from 9 to 85 years with a mean age of 54. The tumor size ranges from 1.7 to 25 cm, with average size of 7.3 cm, and mean survival of 23.73 months. Even though PPUPS has a high local recurrences and mortality rate, long term survival has been reported in some cases, even more than 10 years.[@B005]^,^[@B023]^,^[@B049]^,^[@B052]

###### Review of literature of primary pulmonary undifferentiated pleomorphic sarcoma/primary pulmonary fibrous histiocytoma PPUPS/PPMFH.

  \#   Year   Reference                           Age   Sex   Location   Size (cm)   LN   Tx       Survival (mos)   F/U
  ---- ------ ----------------------------------- ----- ----- ---------- ----------- ---- -------- ---------------- ------
  1    1979   Bedrossian et al.[@B004]            51    M     LLL/RML    3           N    L        14               DOD
  2    1979   Kern et al.[@B017]                  53    M     RLL        8           N    L        12               DOD
  3    1980   Chowdhury et al.[@B007]             52    F     RLL        5           U    C        4                DOD
  4    1981   Paulsen et al.[@B018]               53    F     LLL        4           N    L        36               DOD
  5    1982   Mills et al.[@B019]                 60    F     RLL        10          N    L        18               AWD
  6    1982   Sriumpai et al.[@B020]              41    M     RLL        9           U    L        18               DOD
  7    1983   Misra et al.[@B021]                 45    M     RLL        16          P    X        10               DOD
  8    1984   Larsen et al.[@B022]                75    M     RUL        2.5         N    R        10               NED
  9    1984   Lee et al.[@B023]                   62    M     LLL        6           N    L        12               NED
  10   1984   Lee et al.[@B023]                   54    M     LUL        7           N    C        7                DOD
  11   1984   Lee et al.[@B023]                   69    M     RUL        8           N    Pn,X     8                NED
  12   1984   Lee et al.[@B023]                   62    F     LLL        5           N    L,X      120              NED
  13   1984   Lee et al.[@B023]                   67    M     LUL        4           N    L        60               NED
  14   1984   Lessel and Erbstösser[@B024]        35    F     RLL        25          U    Nt       12               DOD
  15   1984   Silverman and Coalson[@B025]        56    M     LUL        8           \-   C        3                AWD
  16   1985   Tanino et al.[@B026]                75    F     LLL        5           \+   Nt       5                DOD
  17   1986   Venn et al.[@B027]                  32    F     RML/RUL    U           U    L        18               NED
  18   1986   Venn et al.[@B027]                  62    M     RUL        8           U    L        60               NED
  19   1986   Venn et al.[@B027]                  61    F     LUL        U           U    Pn       15               DWED
  20   1986   Venn et al.[@B027]                  62    M     LUL        U           U    X        2                AWD
  21   1987   Hsiu et al.[@B028]                  71    F     RUL        5           N    L        10               NED
  22   1987   Juettner et al.[@B029]              68    M     LLL        20          N    Nt       12               DOD
  23   1987   Juettner et al.[@B029]              58    M     RLL        5.5         P    L        12               DOD
  24   1987   Ismailer et al.[@B030]              12    F     RUL        9           N    L        12               AWD
  25   1987   Yousem and Hochholzer[@B005]        54    F     RLL        1.7         N    L        108              NED
  26   1987   Yousem and Hochholzer[@B005]        33    M     RUL        3.8         N    L        84               NED
  27   1987   Yousem and Hochholzer[@B005]        59    M     RLL        5.9         N    L        65               NED
  28   1987   Yousem and Hochholzer[@B005]        73    F     LUL        8.5         P    Pn       36               NED
  29   1987   Yousem and Hochholzer[@B005]        64    M     RUL        5           N    L,X      16               NED
  30   1987   Yousem and Hochholzer[@B005]        42    F     LLL        3           N    L        122              NED
  31   1987   Yousem and Hochholzer[@B005]        57    F     RUL        4           N    Pn       1                DNED
  32   1987   Yousem and Hochholzer[@B005]        80    M     LUL        3           N    L        1                DNED
  33   1987   Yousem and Hochholzer[@B005]        74    M     LUL        U           N    Nt       2                DOD
  34   1987   Yousem and Hochholzer[@B005]        18    M     RLL        10          N    L        1                DOD
  35   1987   Yousem and Hochholzer[@B005]        46    F     RUL        6           P    L,X      8                DOD
  36   1987   Yousem and Hochholzer[@B005]        52    F     RLL        U           N    C        9                DOD
  37   1987   Yousem and Hochholzer[@B005]        52    F     LUL        4           P    L,C,X    72               DOD
  38   1987   Yousem and Hochholzer[@B005]        74    F     RUL        14          P    L        24               DOD
  39   1987   Yousem and Hochholzer[@B005]        69    F     RUL        8           N    X        36               DOD
  40   1987   Yousem and Hochholzer[@B005]        40    F     LLL        4           N    L,X      24               DOD
  41   1987   Yousem and Hochholzer[@B005]        74    M     RML        U           N    X        8                DOD
  42   1987   Yousem and Hochholzer[@B005]        19    M     LUL        U           N    L,C,X    14               DOD
  43   1987   Yousem and Hochholzer[@B005]        63    M     LLL        7           N    Nt       14               DOD
  44   1987   Yousem and Hochholzer[@B005]        36    M     RLL        3           N    R        12               DOD
  45   1987   Yousem and Hochholzer[@B005]        32    M     LLL        11          P    Pn,C,X   3                DOD
  46   1988   Casey and Peddle[@B031]             21    M     RUL        3           N    L        96               NED
  47   1988   Casey and Peddle[@B031]             46    M     LLL        10          N    L        8                NED
  48   1988   McDonnell et al.[@B032]             73    F     LLL        6.5         N    L        3                DOD
  49   1988   Palmer et al.[@B033]                62    F     RLL        U           N    L        14               DOD
  50   1989   White et al.[@B034]                 55    M     RUL        U           U    Nt       4                DOD
  51   1990   In et al.[@B035]                    43    F     RLL        U           U    C,X      U                U
  52   1990   Marchán and Pérez[@B036]            10    F     LLL        5           N    L        U                U
  53   1993   Higashiyama et al.[@B037]           49    F     RLL        6           P    Pn       U                NED
  54   1995   Kamath et al.[@B038]                56    M     RLL        10          U    Nt       3                DOD
  55   1996   Gómez-Román and Val-Bernal[@B039]   61    M     RUL        3           U    R        9                NED
  56   1996   Halyard et al.[@B040]               51    F     LLL        10          N    L,X      60               NED
  57   1996   Halyard et al.[@B040]               77    M     RML        2.2         N    L        36               NED
  58   1996   Halyard et al.[@B040]               40    M     LLL        11          P    R        6                DOD
  59   1996   Halyard et al.[@B040]               57    F     LUL        7.5         U    L        1                DOD
  60   1996   Shah et al.[@B041]                  9     M     LUL        6           U    L,C,X    36               NED
  61   1997   Nistal et al.[@B042]                12    F     LUL        7           U    C,X      5                AWD
  62   1997   Barbas et al.[@B043]                37    M     RML/RLL    10          N    Pn       6                DNED
  63   2000   Fujita et al.[@B044]                65    F     LLL        12          U    Nt       6                DOD
  64   2000   Herrmann et al.[@B045]              57    M     RUL        13          U    L        12               NED
  65   2001   Nonaka et al.[@B006]                59    M     U          4.5         U    U        U                U
  66   2002   Alhadab et al.[@B046]               56    M     LUL/LLL    U           U    Nt       4                DOD
  67   2002   Etienne-Mastroianni et al.[@B002]   47    M     U          U           U    L,X      3                NED
  68   2003   Wang et al.[@B047]                  86    M     LLL        15          U    Nt       2                DOD
  69   2007   Maeda et al.[@B048]                 62    M     LUL        4.5         P    L        24               DNED
  70   2007   Rzyman et al.[@B049]                58    M     LUL        4           N    Pn       121              NED
  71   2007   Rzyman et al.[@B049]                61    M     RUL        7.5         N    L        7                DNED
  72   2007   Rzyman et al.[@B049]                75    M     RUL        8           P    Pn       4                DOD
  73   2007   Rzyman et al.[@B049]                61    F     LUL        3           N    L        2                DOD
  74   2007   Rzyman et al.[@B049]                54    M     RUL        9           P    L        3                DOD
  75   2008   Noh et al.[@B050]                   58    F     RUL        5           N    L,X      5                NED
  76   2010   Maitani et al.[@B051]               18    F     LUL        2.2         U    L        36               NED
  77   2010   Tsangaridou et al.[@B052]           54    M     LLL        U           N    Pn       168              AWD
  78   2012   Jeon and Park[@B053]                55    M     LLL        U           N    Pn,C,X   9                NED
  79   2012   Thomas and Koshi[@B054]             47    M     RUL        U           P    C,X      2                DOD
  80   2013   Kim et al.[@B008]                   61    M     REB        3           N    E        14               AWD
  81   2013   Li et al.[@B055]                    80    F     RUL        8           U    Nt       1.5              DOD
  82   2014   Liu et al.[@B056]                   59    F     LUL        15.7        N    R        8                NED
  83   2015   Patel et al.[@B057]                 86    M     RML/RLL    9.6         N    L        6                NED
  84   2017   Li et al.[@B058]                    61    M     RUL        8           P    L        U                U
  85   2019   This study                          66    M     RLL        15          N    L,C      4                NED

AWD = alive with disease; C = chemotherapy; DNED = dead with no evidence of disease; DOD = death of disease; DWED = death of non-related cause with evidence of disease; E = endoscopic resection; F/U = follow up; F = female; L = lobectomy; LLL = left lower lobe; LN = lymph node; LUL = left upper lobe; M = male; N = negative; NED = no evidence of disease; Nt = no treatment; Pn = pneumonectomy; P = positive; R = resection; REB = right endobronchial; RLL = right lower lobe; RML = right middle lobe; RUL = right upper lobe; Tx = treatment; U = unavailable data; X = radiotherapy.

CONCLUSION
==========

Primary pulmonary undifferentiated pleomorphic sarcoma (PPUPS) is an exceptionally rare tumor and is essentially a diagnosis of exclusion. The approach should be to first establish the absence of any particular line of differentiation, which requires proper sampling, histological analysis, and immunohistochemistry studies. Other ancillary tests such as molecular studies and electron microscopy could also possibly be helpful. The next step is to exclude any possible extrapulmonary origin by clinical examination or by other means such as PET-CT scan. PPUPS is a highly malignant sarcoma with a poor prognosis, with surgery being the primary treatment in most cases. Postoperative chemotherapy has also been reported to be beneficial in some cases. We report here the only case of PPUPS, which was diagnosed in the past 17 years at UCLA, after an extensive work up. The patient was treated with surgical resection and post-operative chemotherapy. With 4 months follow up, there is no evidence of local recurrence or distant metastasis.
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